Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study.

Rocha J, Aprikian AG, Vanhuyse M, Cury FL, Hu J, Prévost N, Dragomir A.

CMAJ Open. 2017 Mar 28;5(1):E265-E272. doi: 10.9778/cmajo.20160082. eCollection 2017 Jan-Mar.

3.

Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.

Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IP.

Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981. Epub 2016 Dec 20.

4.

Perpetuating effects of androgen deficiency on insulin resistance.

Cameron JL, Jain R, Rais M, White AE, Beer TM, Kievit P, Winters-Stone K, Messaoudi I, Varlamov O.

Int J Obes (Lond). 2016 Dec;40(12):1856-1863. doi: 10.1038/ijo.2016.148. Epub 2016 Aug 18.

5.

Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies.

Scailteux LM, Naudet F, Alimi Q, Vincendeau S, Oger E.

Medicine (Baltimore). 2016 Jun;95(24):e3873. doi: 10.1097/MD.0000000000003873. Review.

6.

Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65-69 Years.

Ryu JH, Kim YB, Jung TY, Kim SI, Byun SS, Kwon DD, Kim DY, Oh TH, Yoo TK, Ko WJ.

J Korean Med Sci. 2016 Jun;31(6):957-62. doi: 10.3346/jkms.2016.31.6.957. Epub 2016 Apr 25.

7.

Long-term Toxicity of Cancer Treatment in Older Patients.

Shahrokni A, Wu AJ, Carter J, Lichtman SM.

Clin Geriatr Med. 2016 Feb;32(1):63-80. doi: 10.1016/j.cger.2015.08.005. Epub 2015 Oct 13. Review.

8.

Impact of Diet-Induced Obesity and Testosterone Deficiency on the Cardiovascular System: A Novel Rodent Model Representative of Males with Testosterone-Deficient Metabolic Syndrome (TDMetS).

Donner DG, Elliott GE, Beck BR, Bulmer AC, Du Toit EF.

PLoS One. 2015 Sep 14;10(9):e0138019. doi: 10.1371/journal.pone.0138019. eCollection 2015.

9.

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.

Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9.

10.

The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada.

Davis MK, Rajala JL, Tyldesley S, Pickles T, Virani SA.

J Oncol. 2015;2015:820403. doi: 10.1155/2015/820403. Epub 2015 Aug 2.

11.

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.

Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA.

Eur J Cancer. 2015 May;51(7):817-24. doi: 10.1016/j.ejca.2015.03.003. Epub 2015 Mar 17.

12.

Identification of microRNA-mRNA dysregulations in paroxysmal atrial fibrillation.

Chiang DY, Zhang M, Voigt N, Alsina KM, Jakob H, Martin JF, Dobrev D, Wehrens XH, Li N.

Int J Cardiol. 2015 Apr 1;184:190-7. doi: 10.1016/j.ijcard.2015.01.075. Epub 2015 Jan 28.

13.

Metabolic effects of androgen deprivation therapy.

Choi SM, Kam SC.

Korean J Urol. 2015 Jan;56(1):12-8. doi: 10.4111/kju.2015.56.1.12. Epub 2015 Jan 6. Review.

14.

Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.

Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA, Penson DF.

J Urol. 2015 Apr;193(4):1226-31. doi: 10.1016/j.juro.2014.11.006. Epub 2014 Nov 11.

15.

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.

PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.

16.

Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.

Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Penson DF.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):338-42. doi: 10.1038/pcan.2014.31. Epub 2014 Aug 19.

17.

Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.

Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, Saigal C; Urologic Diseases in America Project..

Cancer. 2014 Dec 1;120(23):3642-50. doi: 10.1002/cncr.28926. Epub 2014 Jul 17.

18.

Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions.

Bradley CJ, Dahman B, Anscher M.

Med Care. 2014 Jun;52(6):482-9. doi: 10.1097/MLR.0000000000000113.

19.

Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.

Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK, Lam KS, Tse HF, Yau T, Siu CW.

J Oncol. 2014;2014:529468. doi: 10.1155/2014/529468. Epub 2014 Apr 7.

20.

Supplemental Content

Support Center